These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 3778067)

  • 21. Effects of deferoxamine on renal function in thalassemia.
    Hyman CB; Gonick HC; Agness C; Nadorra R; Landing B
    Birth Defects Orig Artic Ser; 1988; 23(5B):135-40. PubMed ID: 3390536
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical and echocardiographic evaluation of thalassemic cardiomyopathy].
    Sau F; Lai ME; Pargentino E; Seguro C; Pilloni MI; Lisci V; Guaita B; Naccarato S; Pisanu S; Figus R
    Cardiologia; 1995 May; 40(5):307-14. PubMed ID: 8529242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW; Winchester P; Giardina PJ; Cunningham-Rundles S
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment of Cooley's anemia. Intravenous chelation therapy.
    Cohen AR; Martin M; Schwartz E
    Ann N Y Acad Sci; 1990; 612():286-92. PubMed ID: 2291556
    [No Abstract]   [Full Text] [Related]  

  • 25. Can deferoxamine be considered an ototoxic drug?
    Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
    Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron chelation in thalassemia.
    Pippard MJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):35-40. PubMed ID: 3390560
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose chelation therapy in thalassaemia.
    Lancet; 1984 Feb; 1(8373):373-4. PubMed ID: 6141429
    [No Abstract]   [Full Text] [Related]  

  • 28. Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C?
    Leonardi S; Musumeci S
    Acta Haematol; 1993; 90(4):211-2. PubMed ID: 8140864
    [No Abstract]   [Full Text] [Related]  

  • 29. The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran.
    Karimi M; Haghpanah S
    Health Policy; 2015 Feb; 119(2):239-43. PubMed ID: 25564279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children.
    Benso L; Gambotto S; Pastorin L; Signorile F; Tanner JM
    Eur J Pediatr; 1995 Mar; 154(3):205-8. PubMed ID: 7758518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic evaluation of children with homozygous beta-thalassemia treated with desferrioxamine.
    Speer CP; Gahr M; Schuff-Werner P; Schröter W
    Acta Haematol; 1990; 83(2):76-81. PubMed ID: 2106199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents.
    Al-Kloub MI; Salameh TN; Froelicher ES
    Int J Nurs Pract; 2014 Jun; 20(3):265-74. PubMed ID: 24888999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute changes in renal function associated with deferoxamine therapy.
    Koren G; Bentur Y; Strong D; Harvey E; Klein J; Baumal R; Spielberg SP; Freedman MH
    Am J Dis Child; 1989 Sep; 143(9):1077-80. PubMed ID: 2486554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia.
    Olivieri NF; Freedman MH; Perrine SP; Dover GJ; Sheridan B; Essentine DL; Nagel RL
    Blood; 1992 Dec; 80(12):3258-60. PubMed ID: 1467532
    [No Abstract]   [Full Text] [Related]  

  • 35. Drugs in current use: thalassaemia.
    Cromdos S
    Aust Nurses J; 1978 Sep; 8(3):30-1. PubMed ID: 251094
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of the one sample t-test in the real world.
    Cressie NA; Sheffield LJ; Whitford HJ
    J Chronic Dis; 1984; 37(2):107-14. PubMed ID: 6693529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological and toxic properties of deferoxamine.
    Freedman MH; Bentur Y; Koren G
    Prog Clin Biol Res; 1989; 309():115-24. PubMed ID: 2675081
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute changes in renal function associated with deferoxamine therapy.
    Li Volti S; Di Gregorio F; Schilirò G
    Am J Dis Child; 1990 Oct; 144(10):1069-70. PubMed ID: 2264886
    [No Abstract]   [Full Text] [Related]  

  • 39. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice.
    Sindrilaru A; Peters T; Wieschalka S; Baican C; Baican A; Peter H; Hainzl A; Schatz S; Qi Y; Schlecht A; Weiss JM; Wlaschek M; Sunderkötter C; Scharffetter-Kochanek K
    J Clin Invest; 2011 Mar; 121(3):985-97. PubMed ID: 21317534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of sex steroids in patients with beta thalassaemia major.
    Katz M; De Sanctis V; Vullo C; Wonke B; McGarrigle HH; Bagni B
    J Clin Pathol; 1993 Jul; 46(7):660-4. PubMed ID: 8157756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.